What is the prevalence of mutations in CEBPA in acute myeloid leukemia (AML)?

Updated: May 26, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Mutations in CEBPA are detected in 15% of patients with normal cytogenetics findings. Biallelic mutations are associated with a longer remission duration and longer overall survival. [33] ERG overexpression is an adverse predictor in cytogenetically normal AML.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!